
Tamer Elbaz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7572061/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>Schistosoma mansoni</i> infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade. Pathogens and Global Health, 2022, 116, 119-127.	2.3	4
2	Plasma cell-free DNA integrity index and hepatocellular carcinoma treated or not with direct-acting antivirals: A case-control study. Arab Journal of Gastroenterology, 2022, 23, 39-44.	0.9	1
3	Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Current Medical Research and Opinion, 2022, 38, 553-563.	1.9	0
4	The Role of Interleukin 1 Beta in Differentiating Malignant from Benign Pancreatic Cysts. Journal of Interferon and Cytokine Research, 2022, 42, 118-126.	1.2	2
5	Egypt: Towards Successful Elimination of HCV in Low-Income Countries. , 2021, , 229-235.		0
6	Pregnancy outcome of antiâ€HCV directâ€acting antivirals: Realâ€life data from an Egyptian cohort. Liver International, 2021, 41, 1494-1497.	3.9	15
7	Role of circulating microRNA-21 and microRNA-215 in the diagnosis of hepatitis C related hepatocellular carcinoma. Journal of Infection in Developing Countries, 2021, 15, 997-1003.	1.2	1
8	Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Review of Anti-Infective Therapy, 2021, , 1-8.	4.4	4
9	Hepatocellular Carcinoma Multidisciplinary Clinic-Cairo University (HMC-CU) score: A new simple score for diagnosis of HCC. Arab Journal of Gastroenterology, 2020, 21, 102-105.	0.9	7
10	Machine Learning Prediction Models for Diagnosing Hepatocellular Carcinoma with HCV-related Chronic Liver Disease. Computer Methods and Programs in Biomedicine, 2020, 196, 105551.	4.7	41
11	Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Review of Anti-Infective Therapy, 2020, 18, 637-642.	4.4	13
12	Predictors of recurrence and survival of hepatocellular carcinoma: A prospective study including transient elastography and cancer stem cell markers. Arab Journal of Gastroenterology, 2020, 21, 95-101.	0.9	4
13	Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	4
14	Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. Journal of Medical Virology, 2019, 91, 272-277.	5.0	20
15	Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review. Journal of Advanced Research, 2019, 17, 43-48.	9.5	13
16	Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma. Journal of Medical Virology, 2019, 91, 1537-1544.	5.0	4
17	HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Review of Anti-Infective Therapy, 2018, 16, 345-350.	4.4	43
18	Novel scores combining AFP with nonâ€invasive markers for prediction of liver fibrosis in chronic hepatitis C patients. Journal of Medical Virology, 2018, 90, 1080-1086.	5.0	18

TAMER ELBAZ

#	Article	IF	CITATIONS
19	Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after directâ€acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort. Journal of Medical Virology, 2018, 90, 1508-1515.	5.0	8
20	Effectiveness of ravidasvir plus sofosbuvir in interferon-naÃ ⁻ ve and treated patients with chronic hepatitis C genotype-4. Journal of Hepatology, 2018, 68, 53-62.	3.7	17
21	A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ravidasvir. Current Drug Discovery Technologies, 2018, 15, 24-31.	1.2	6
22	Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. European Journal of Gastroenterology and Hepatology, 2018, 30, 882-887.	1.6	6
23	Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Expert Opinion on Drug Discovery, 2017, 12, 635-642.	5.0	13
24	Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. Journal of Interferon and Cytokine Research, 2017, 37, 348-353.	1.2	4
25	Magnetic resonance sialography of the parotid glands in chronic hepatitis C virus patients with and without vasculitis. International Journal of Rheumatic Diseases, 2017, 20, 376-382.	1.9	0
26	Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic <scp>HCV</scp> genotype <scp>IV</scp> infected patients. Liver International, 2017, 37, 534-541.	3.9	51
27	Portal Vein Thrombosis in Unresectable Hcc Cases: a Single Center Study of Prognostic Factors and Management in 140 Patients. Asian Pacific Journal of Cancer Prevention, 2017, 18, 183-188.	1.2	4
28	Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2017, 18, 189-194.	1.2	24
29	GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2016, 58, 88.	1.1	7
30	Management of Hepatitis C Virus—Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status. Current Treatment Options in Infectious Diseases, 2016, 8, 368-378.	1.9	0
31	Role of MRI in the assessment of treatment response after radiofrequency and microwave ablation therapy for hepatocellular carcinoma. Egyptian Journal of Radiology and Nuclear Medicine, 2016, 47, 377-385.	0.6	10
32	Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Review of Clinical Pharmacology, 2016, 9, 1413-1421.	3.1	13
33	Safety of direct antiviral agents in the management of hepatitis C. Expert Opinion on Drug Safety, 2016, 15, 1643-1652.	2.4	36
34	Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma. Tumor Biology, 2016, 37, 211-216.	1.8	33
35	Value of microwave ablation in treatment of large lesions of hepatocellular carcinoma. Journal of Digestive Diseases, 2015, 16, 456-463.	1.5	38
36	Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scandinavian Journal of Gastroenterology, 2015, 50, 479-484.	1.5	41

TAMER ELBAZ

#	Article	IF	CITATIONS
37	New era for management of chronic hepatitis C virus using direct antiviral agents: A review. Journal of Advanced Research, 2015, 6, 301-310.	9.5	40
38	Interferon-Î ³ and Interleukin-10 Gene Polymorphisms are not Predictors of Chronic Hepatitis C (Genotype-4) Disease Progression. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5025-5030.	1.2	10
39	Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6923-6928.	1.2	16
40	Predictors of Disease Recurrence Post Living Donor Liver Transplantation in End Stage Chronic HCV Patients. Disease Markers, 2014, 2014, 1-9.	1.3	4
41	The Efficacy of a <i>Hansenula</i> -Derived 20 kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2014, 34, 727-733.	1.2	3
42	Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an egyptian multidisciplinary clinic experience. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 3429-3434.	2.4	106
43	Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3915-3920.	1.2	35
44	A retrospective evaluation of causes of exempting living liver donors in an Egyptian centre. Arab Journal of Gastroenterology, 2013, 14, 10-13.	0.9	2
45	Hepatic and Intestinal Schistosomiasis: Review. Journal of Advanced Research, 2013, 4, 445-452.	9.5	161
46	Management of Hepatocellular Carcinoma: Updated Review. Journal of Cancer Therapy, 2013, 04, 536-545.	0.4	13
47	Thrombotic thrombocytopenic purpura associated with chronic HCV infection. Egyptian	1.0	3